Relevant bibliographies by topics / 61:658.011.56(0432)

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic '61:658.011.56(0432)'

Author: Grafiati
Published: 30 May 2022
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '61:658.011.56(0432).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "61:658.011.56(0432)"

1

Fares-Otero, N. E., B. Solé, S. Martin-Parra, et al. "Mindfulness, Attention, and Impulsivity in Bipolar Disorder." European Psychiatry 66, S1 (2023): S84—S85. http://dx.doi.org/10.1192/j.eurpsy.2023.262.

Full text
Abstract:
IntroductionBipolar disorder (BD) is a chronic mental disorder characterized by mood instability1. BD is further related to neurocognitive and functional disruptions that remain remarkably stable even when patients are euthymic, leading to poor well-being and quality of life. Mindfulness means paying attention on purpose, in the present moment, and involves different facets such as observing, describing, acting with awareness, non-judging and non-reacting of inner experience. It remains unclear whether mindfulness and its specific facets are differentially associated with different aspects of
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Megan, Molly Schiffer, Iris Isufi, et al. "Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas." Blood 136, Supplement 1 (2020): 21–22. http://dx.doi.org/10.1182/blood-2020-139790.

Full text
Abstract:
Introduction While the approved dose of brentuximab in T cell lymphomas has been every 3 weeks on a 1.8 mg/kg schedule, earlier studies exploring weekly dosing showed that a dose of 1.2 mg/kg on a weekly dosing (every 3 out of 4 weeks) in pts with Hodgkin's lymphoma and hematologic malignancies may improve cancer response rates while still having manageable side effects3. We explored the weekly dosing schedule in 37 pts (pts) with mycosis fungoides/Sezary syndrome (MF/SS) and aggressive T cell lymphomas and compared to our experience with every 3 week dosing in 36 pts to evaluate tolerability
APA, Harvard, Vancouver, ISO, and other styles
3

Costa, Bruno Marques, Paulo Ferreira, Sandra Costa, et al. "Association between Functional EGF+61 Polymorphism and Glioma Risk." Clinical Cancer Research 13, no. 9 (2007): 2621–26. http://dx.doi.org/10.1158/1078-0432.ccr-06-2606.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jardim, Denis L., Kenneth R. Hess, Patricia LoRusso, Razelle Kurzrock, and David S. Hong. "Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs." Clinical Cancer Research 20, no. 2 (2013): 281–88. http://dx.doi.org/10.1158/1078-0432.ccr-13-2103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cleary, James M., Victoria Wang, Rebecca S. Heist, et al. "Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors." Clinical Cancer Research 27, no. 11 (2021): 2996–3004. http://dx.doi.org/10.1158/1078-0432.ccr-21-0066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Arend, Rebecca C., Carly B. Scalise, Emily R. Gordon, et al. "Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC." Clinical Cancer Research 28, no. 7 (2022): 1433–45. http://dx.doi.org/10.1158/1078-0432.ccr-21-2984.

Full text
Abstract:
Abstract Purpose: Our study used transcriptomic and metabolomic strategies to determine the molecular profiles of HGSOC patient samples derived from primary tumor and ascites cells. These data identified clinically relevant heterogeneity among and within patients and highlighted global and patient-specific cellular responses to neoadjuvant chemotherapy (NACT). Experimental Design: Tissue from 61 treatment-naïve patients with HGSOC were collected. In addition, 11 benign, 32 ascites, and 18 post-NACT samples (matched to the individual patient's pre-NACT sample) were collected. RNA sequencing (RN
APA, Harvard, Vancouver, ISO, and other styles
7

Wesseling, Jelle. "Abstract F1-2: Clonal evolution of DCIS to invasion." Cancer Research 83, no. 5_Supplement (2023): F1–2—F1–2. http://dx.doi.org/10.1158/1538-7445.sabcs22-f1-2.

Full text
Abstract:
Abstract Clonal evolution of DCIS to invasion Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive breast cancer (IBC). If not treated, at least 3 out of 4 women with DCIS will not develop IBC1-3. This implies many women with non-progressive, low-risk DCIS are likely to carry the burden of overtreatment. To solve this DCIS dilemma, two fundamental questions need to be answered. The first question is, how the subsequent IBC is related to the initial DCIS lesion. The seco
APA, Harvard, Vancouver, ISO, and other styles
8

Else, Tobias, Eric Jonasch, Othon lliopoulos, et al. "Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study." Clinical Cancer Research, February 23, 2024. http://dx.doi.org/10.1158/1078-0432.ccr-23-2592.

Full text
Abstract:
Abstract Purpose: Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment. We describe results of belzutifan treatment for VHL disease-associated pancreatic lesions (pancreatic neuroendocrine tumors [pNETs] and serous cystadenomas). Patients and Methods: Adults with VHL diagnosis based on germline VHL alteration, ≥1 measurable RCC tumor, no renal tumor >3 cm or other VHL neoplasm requiring im
APA, Harvard, Vancouver, ISO, and other styles
9

Allan, John N., Ian W. Flinn, Tanya Siddiqi, et al. "Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia." Clinical Cancer Research, June 7, 2023, OF1—OF9. http://dx.doi.org/10.1158/1078-0432.ccr-22-2779.

Full text
Abstract:
Abstract Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes of fixed-duration ibrutinib plus venetoclax in patients with high-risk genomic features [del(17p), TP53 mutation, and/or unmutated immunoglobulin heavy chain (IGHV)] in CAPTIVATE. Patients and Methods: Patients received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). FD
APA, Harvard, Vancouver, ISO, and other styles
10

Patel, Timil H., Amy Corneli, Pamela Balcazar, et al. "Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals During COVID-19." Clinical Cancer Research, March 4, 2025. https://doi.org/10.1158/1078-0432.ccr-24-3357.

Full text
Abstract:
Abstract The COVID-19 pandemic disrupted cancer clinical trials, prompting sponsors to adopt decentralized clinical trial (DCT) elements to ensure patient safety and trial continuity. Supported by FDA emergency guidance, the FDA Oncology Center of Excellence, in collaboration with the Clinical Trials Transformation Initiative (CTTI), conducted an assessment of DCT elements in cancer trials leading to FDA approval during the pandemic. Between December 6, 2022, and January 17, 2023, CTTI collected survey data from trial sponsors about DCT elements used in response to the pandemic, implementation
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "61:658.011.56(0432)"

1

Коваль, Аліна Володимирівна, та Ольга Борисівна Іванець. "СТВОРЕННЯ АВТОМАТИЗОВАНОЇ СИСТЕМИ ЗБОРУ ТА ПРОГРАМНОГО АНАЛІЗУ МЕДИЧНОЇ ІНФОРМАЦІЇ ДЛЯ ВИЗНАЧЕННЯ ПРИДАТНОСТІ КАНДИДАТІВ ДО УЧАСТІ У АНТАРКТИЧНІЙ ЕКСПЕДИЦІЇ". Thesis, VIII Міжнародна антарктична конференція, присвячена 25-річчю приєднання Україна до договору про Антарктиду, 2017. https://er.nau.edu.ua/handle/NAU/47924.

Full text
Abstract:
Створено медичну базу даних з автоматизованою системою збору інформації та програмним забезпеченням оперативного аналізу біомедичних показників для визначення параметрів придатності за станом здоров’я до роботи на антарктичній станції.
APA, Harvard, Vancouver, ISO, and other styles
2

Бреус, Анна Миколаївна. "РОЗРАХУНОК РИЗИКІВ МЕДИЧНОГО СТРАХУВАННЯ ПОЛЯРНИКІВ". Thesis, VIII Міжнародна антарктична конференція, присвячена 25-річчю приєднання Україна до договору про Антарктиду, 2017. https://er.nau.edu.ua/handle/NAU/47914.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '61:658.011.56(0432)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography